Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol (NCT01533376) | Clinical Trial Compass
TerminatedPhase 1
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
United States3 participantsStarted 2012-02
Plain-language summary
Primary Objective:
• To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
Who can participate
Age range2 Years – 10 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Age from 2 years to 10 years
* Port-Wine Mark
* English fluent and literate substitute decision maker
* Substitute decision maker vision sufficient to read informed consent document
Exclusion criteria:
* Active ocular infection (conjunctivitis, keratitis,)
* History of systemic conditions including hypo/hypertension, hypoglycemia, bradycardia, asthma or any contraindication to beta blocker use
* Unable to comply with required follow-up
* Substitute decision maker not English fluent or not literate
* Substitute decision maker unable to read consent document
* Patient already using systemic beta-blocker or beta-agonist (Patients already using topical beta-blocker for glaucoma will not be excluded from study).